Captopril as a potential inhibitor of lung tumor growth and metastasis

Annals of the New York Academy of Sciences

Volumn 1138, Issue , 2008, Pages 65-72

  Attoub, Samir ^a   Gaben, Anne Marie ^b   Al Salam, Suhail ^a   Al Sultan, M A H ^a   John, Anne ^a   Nicholls, M Gary ^a   Mester, Jan ^b   Petroianu, Georg ^a  

^a UNITED ARAB EMIRATES UNIVERSITY   (United Arab Emirates)

^b HÔPITAL SAINT ANTOINE   (France)

Author keywords

Captopril; Lung tumor; Metastasis

Indexed keywords

CAPTOPRIL; CD31 ANTIGEN; KI 67 ANTIGEN;

ANGIOGENESIS; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BODY WEIGHT; CANCER CELL; CANCER INHIBITION; CELL PROLIFERATION; CELL SELECTION; CELL VIABILITY; CONFERENCE PAPER; CONTROLLED STUDY; FEMALE; FLUORESCENCE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LUNG CANCER; LYMPH NODE METASTASIS; MOUSE; NONHUMAN; NUDE MOUSE; TUMOR GROWTH; TUMOR XENOGRAFT;

ANIMALIA; MUS;

EID: 53149097024     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1196/annals.1414.011     Document Type: Conference Paper

References (30)

1. Lever, A.F., D.J. Hole, C.R. Gillis, et al. 1998. Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer? Lancet 352 : 179 184.
2. Bader, M., J. Peters, O. Baltatu, et al. 2001. Tissue renin-angiotensin systems: new insights from experimental animal models in hypertension research. J. Mol. Med. 79 : 76 102.
3. Otani, A., H. Takagi, K. Suzuma & Y. Honda. 1998. Angiotensin II potentiates vascular endothelial growth factor-induced angiogenic activity in retinal microcapillary endothelial cells. Circ. Res. 82 : 619 628.
4. Tamarat, R., J.S. Silvestre, M. Durie & B.I. Levy. 2002. Angiotensin II angiogenic effect in vivo involves vascular endothelial growth factor- and inflammation-related pathways. Lab. Invest. 82 : 747 756.
5. Egami, K., T. Murohara, T. Shimada, et al. 2003. Role of host angiotensin II type 1 receptor in tumor angiogenesis and growth. J. Clin. Invest. 112 : 67 75.
6. Fujita, M., I. Hayashi, S. Yamashina, et al. 2005. Angiotensin type 1a receptor signaling-dependent induction of vascular endothelial growth factor in stroma is relevant to tumor-associated angiogenesis and tumor growth. Carcinogenesis 26 : 271 279.
7. Horiuchi, M., W. Hayashida, M. Akishita, et al. 1999. Stimulation of different subtypes of angiotensin II receptors, AT1 and AT2 receptors, regulates STAT activation by negative crosstalk. Circ. Res. 84 : 876 882.
8. Rivat, C., S. Rodrigues, E. Bruyneel, et al. 2005. Implication of STAT3 signaling in human colonic cancer cells during Intestinal Trefoil Factor (TFF3) and VEGF-mediated cellular invasion and tumor growth. Cancer Res. 65 : 195 202.
9. Prevost, G.P., M.O. Lonchampt, S. Holbeck, et al. 2006. The novel inhibitor of heterotrimeric G-protein signaling BIM-46174, enhances the anticancer activity of cisplatin in human NSCLC lung tumor xenografts. Cancer Res. 66 : 9227 9234.
10. Wolf, G. & U.O. Wenzel. 2004. Angiotensin II and cell cycle regulation. Hypertension 43 : 693 698.
11. Escobar, E., T.S. Rodriguez-Reyna, O. Arrieta & J. Sotelo. 2004. Angiotensin II, cell proliferation and angiogenesis regulator: biologic and therapeutic implications in cancer. Curr. Vasc. Pharmacol. 2 : 385 399.
12. Hama, K., H. Ohnishi, H. Yasuda, et al. 2004. Angiotensin II stimulates DNA synthesis of rat pancreatic stellate cells by activating ERK through EGF receptor transactivation. Biochem. Biophys. Res. Commun. 315 : 905 911.
13. Petroianu, G., E Adeghate, Mohd Hassan, et al. 2004. Intraperitoneal exposure to captopril but not to lisinopril activates the peroxisome proliferator activated receptor (PPAR). Clin. Exp. Pharmacol. Physiol. 31 (Suppl 1 A100.
14. Jackson, L., W. Wahli, L. Michalik, et al. 2003. Potential role for peroxisome proliferator activated receptor (PPAR) in preventing colon cancer. Gut 52 : 1317 1322.
15. Zhang, M., P. Zou, M. Bai, et al. 2003. Apoptosis of human lung cancer cells induced by activated peroxisome proliferator-activated receptor-gamma and its mechanism. Zhonghua Yi Xue Za Zhi 83 : 1169 1172.
16. Volpert, O.V., W.F. Ward, M.W. Lingen, et al. 1996. Captopril inhibits angiogenesis and slows the growth of experimental tumors in rats. J. Clin. Invest. 98 : 671 679.
17. Buemi, M., A. Allegra, D. Marino, et al. 1999. Does captopril have a direct pro-apoptotic effect? Nephron 81 : 99 101.
18. Fabre, J.E., A. Rivard, M. Magner, et al. 1999. Tissue inhibition of angiotensin-converting enzyme activity stimulates angiogenesis in vivo. Circulation 99 : 3043 3049.
19. Silvestre, J.S., S. Bergaya, R. Tamarat, et al. 2001. Proangiogenic effect of angiotensin-converting enzyme inhibition is mediated by the bradykinin B(2) receptor pathway. Circ. Res. 89 : 678 683.
20. Ebrahimian, T.G., R. Tamarat, M. Clergue, et al. 2005. Dual effect of angiotensin-converting enzyme inhibition on angiogenesis in type 1 diabetic mice. Arterioscler Thromb. Vasc. Biol. 25 : 65 70.
21. Yoshiji, H., S. Kuriyama, M. Kawata, et al. 2001. The angiotensin-I-converting enzyme inhibitor perindopril suppresses tumor growth and angiogenesis: possible role of the vascular endothelial growth factor. Clin. Cancer Res. 7 : 1073 1078.
22. Lindholm, L.H., H. Anderson, T. Ekbom, et al. 2001. Relation between drug treatment and cancer in hypertensives in the Swedish Trial in Old Patients with Hypertension 2: a 5-year, prospective, randomised, controlled trial. Lancet 358 : 539 544.
23. Hii, S.I., D.L. Nicol, D.C. Gotley, et al. 1998. Captopril inhibits tumour growth in a xenograft model of human renal cell carcinoma. Br. J. Cancer 77 : 880 883.
24. Yasumatsu, R., T. Nakashima, M. Masuda, et al. 2004. Effects of the angiotensin-I converting enzyme inhibitor perindopril on tumor growth and angiogenesis in head and neck squamous cell carcinoma cells. J. Cancer Res. Clin. Oncol. 130 : 567 573.
25. Chisi, J.E., C.V. Briscoe, E. Ezan, et al. 2000. Captopril inhibits in vitro and in vivo the proliferation of primitive haematopoietic cells induced into cell cycle by cytotoxic drug administration or irradiation but has no effect on myeloid leukaemia cell proliferation. Br. J. Haematol. 109 : 563 570.
26. Nakagawa, T., T. Kubota, M. Kabuto & T. Kodera. 1995. Captopril inhibits glioma cell invasion in vitro: involvement of matrix metalloproteinases. Anticancer Res. 15 : 1985 1989.
27. Kikkawa, F., M. Mizuno, K. Shibata, et al. 2004. Activation of invasiveness of cervical carcinoma cells by angiotensin II. Am. J. Obstet. Gynecol. 190 : 1258 1263.
28. Nguyen, Q.D., S. Rodrigues, C. Rodrigue, et al. 2006. Inhibition of VEGF-165 and Semaphorin 3A-mediated cellular invasion and tumor growth by the VEGF signaling inhibitor ZD4190 in human colon cancer cells and xenografts. Mol. Cancer Ther. 5 : 2070 2077.
29. Merchan, J.R., B. Chan, S. Kale, et al. 2003. In vitro and in vivo induction of antiangiogenic activity by plasminogen activators and captopril. J. Natl. Cancer Inst. 95 : 388 399.
30. Stanojkovic, T.P., Z. Zizak, N. Mihailovic-Stanojevic, et al. 2005. Inhibition of proliferation on some neoplastic cell lines-act of carvedilol and captopril. J. Exp. Clin. Cancer Res. 24 : 387 395.